Karyopharm Therapeutics, Inc.

( )
KPTI After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 0.99%59.150.0%$907.20m
AMGNAmgen, Inc. -0.77%256.251.3%$749.53m
GILDGilead Sciences, Inc. 0.54%76.761.0%$694.38m
REGNRegeneron Pharmaceuticals, Inc. 0.77%627.252.5%$662.27m
BIIBBiogen, Inc. 1.77%269.801.6%$578.06m
NVAXNovavax, Inc. -2.70%79.44102.0%$554.12m
VRTXVertex Pharmaceuticals, Inc. 0.07%291.311.9%$511.41m
ILMNIllumina, Inc. 1.69%379.393.5%$304.71m
ALXNAlexion Pharmaceuticals, Inc. 1.13%113.572.0%$235.48m
BMRNBioMarin Pharmaceutical, Inc. 0.73%127.714.3%$217.46m
SGENSeattle Genetics, Inc. 0.84%170.456.1%$198.74m
SRNESorrento Therapeutics, Inc. 4.60%7.171.8%$192.02m
IMMUImmunomedics, Inc. 8.23%40.6311.0%$178.71m
SRPTSarepta Therapeutics, Inc. 0.46%163.4913.9%$171.15m
INCYIncyte Corp. 1.24%107.792.5%$164.33m

Company Profile

Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.